These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 3172370)

  • 21. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
    Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
    Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How safe is the treatment of impotence with intracavernous autoinjection?
    Zentgraf M; Ludwig G; Ziegler M
    Eur Urol; 1989; 16(3):165-71. PubMed ID: 2663519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic erection program for the treatment of male impotence.
    Trapp JD
    South Med J; 1987 Apr; 80(4):426-7. PubMed ID: 2436316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury.
    Sidi AA; Cameron JS; Dykstra DD; Reinberg Y; Lange PH
    J Urol; 1987 Sep; 138(3):539-42. PubMed ID: 2442418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penile corporeal fibrosis complicating papaverine self-injection therapy for erectile impotence.
    Desai KM; Gingell JC
    Eur Urol; 1988; 15(1-2):132-3. PubMed ID: 3215228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracavernous injections for impotence.
    Med Lett Drugs Ther; 1987 Oct; 29(751):95-6. PubMed ID: 3670212
    [No Abstract]   [Full Text] [Related]  

  • 29. Intracavernous self-injection for erectile failure.
    Ruutu M; Lindström BL; Virtanen J; Alfthan O
    Eur Urol; 1988; 15(1-2):96-8. PubMed ID: 3215245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risks of self-injection therapy for impotence.
    Millard RJ; Stricker PD; Lynch WJ; Dean TE; Murnaghan GF; Breslin FH
    Med J Aust; 1996 Jul; 165(2):117-8. PubMed ID: 8692055
    [No Abstract]   [Full Text] [Related]  

  • 32. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic roles of intracavernosal papaverine.
    Goldstein I; Payton T; Padma-Nathan H
    Cardiovasc Intervent Radiol; 1988 Aug; 11(4):237-9. PubMed ID: 3147138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologically induced erections among geriatric men.
    Kerfoot WW; Carson CC
    J Urol; 1991 Oct; 146(4):1022-4. PubMed ID: 1895417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of vasoactive agents in the treatment of erectile impotence.
    Fried FA
    N C Med J; 1990 Jun; 51(6):295-6. PubMed ID: 2366889
    [No Abstract]   [Full Text] [Related]  

  • 36. [Papaverine-induced priapism. Experiences with a new urologic emergency].
    Schneider AW; Busch R; Gonnermann D; Klosterhalfen H
    Dtsch Med Wochenschr; 1989 Feb; 114(6):214-7. PubMed ID: 2917481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
    Kiely EA; Bloom SR; Williams G
    Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.
    Larsen EH; Gasser TC; Bruskewitz RC
    J Urol; 1987 Feb; 137(2):292-3. PubMed ID: 3806824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification of sexual dysfunction for management of intracavernous medication-induced erections.
    Fein RL
    J Urol; 1990 Feb; 143(2):298-301. PubMed ID: 1688954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.